0
Products in the cart
Total:
Information block example
Currency
English Support
Request a call
Working hours:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00

Darbelife 40mcg

Darbelife 40mcg (Darbepoetin alfa)

Darbelife   40mcg             is indicated for the conditions as follows;
• The treatment in patients with Anemia associated with chronic kidney disease (CKD).
• The treatment in patients with Anemia is caused by chemotherapy cancer treatment but it is a support medication, it will not treat cancer
• The treatment in patients with Symptomatic Anemia associated with myelodysplastic syndromes (MDS).

Feature
Brand name:
Darbelife
Active substance:
Darbepoetin alfa 40mcg
Manufacturer:
Hetero Drugs Ltd.
Packaging:
1 PFS
Product form:
Injection
In stock
Active substance: Darbepoetin alfa
0 $
Available options:
Amount:
To wishlist
Compared
Consulting:+91(994)0472902
Description

DESCRIPTION

Darbepoetin alfa is a generic form of brand name of Darbelife   40mcg
Darbelife   40mcg             injection causes the bone marrow to produce red blood cells. If the body does not produce suitable red blood cells, severe Anemia can occur. This frequentlyresults in people with chronic kidney failure whose kidneys are not proper working.
Darbelife   40mcg             may be prescribed for patients on kidney dialysis or for those not on dialysis.
Darbelife   40mcg             is a prescription drug which is used under the guidance of medical practioners.

INDICATION

Darbelife   40mcg             is indicated for the conditions as follows;
• The treatment in patients with Anemia associated with chronic kidney disease (CKD).
• The treatment in patients with Anemia is caused by chemotherapy cancer treatment but it is a support medication, it will not treat cancer
• The treatment in patients with Symptomatic Anemia associated with myelodysplastic syndromes (MDS).

MECHANISM OF ACTION

Darbepoetin consist of Recombinant human erythropoietin with sialic acid additions to have high stability; provoke erythropoiesis via division &differentiation of progenitor cells in bone marrow to activate the release of reticulocytes from the bone marrow into the bloodstream to form erythrocytes.

ADME PROPERTIES

Absorption

Low absorption

Distribution

Duration to high plasma concentration is 34 hr subcutaneously (SC)

Metabolism

For adult Bioavailability is 37% SC and children is 54% SC

Elimination

Volume of distribution is 0.06L/kg
Half-life is 46 hr (SC) and if IV then 21 hr.

DOSAGE AND ADMINISTRATION

The dose of this medication will be varied for different patients.
Anemia from chronic kidney failure :
The dose adopted for adults and children – dose primarily based on body weight
The started recommended dose is 0.45 to 0.75 mcg/kg of body weight injected via IV or SC (under the skin) once a week or once every week.
Your doctor may adjust the dose as required.
Anemia from cancer chemotherapy :
Dose is based on body weight for adult
The starting recommended dose is 2.40mcg             once every 3 weeks injected under the skin.
The dose for children and use should be decided by your doctor

SIDE EFFECTS

The side effects caused by Darbelife   40mcg             as follows :
Common side effects :
Dyspnea
Cough
During dialysis causes hypotension
Abdominal tenderness
Edema of the arms or legs.
Serious side effects :
Increased hypertension
Seizures
Severe allergic reaction: wheezing, dizziness, skin rash, itching

PRECAUTION

Devaluation of dose if Hgb increase exceeds 1 g/dL in any 2-week period
When treatment with Darbelife   40mcg             greater the mortality and/or raise risk of tumor development or recurrent in patients with cancer
The Darbelife   40mcg             has increased risk for seizures in patients with CKD; increase monitoring of these patients for changes in seizure frequency or premonitory symptoms.
Darbelife   40mcg             injection will leads toincrease mortality, myocardial infarction, stroke, and thromboembolism: Using ESAs to aims a haemoglobin level of higher than 11 g/dL raises the risk of serious adverse cardiovascular reactions
Darbelife   40mcg             injection will causes known porphyria, sickle cell Anemia, thalassemia in patients
If severe Anemia and low reticulocyte count results during treatment, detain treatment and check out for pure red cell aplasia.

DRUG INTERACTION

No drug interaction involved in the drug Darbelife   40mcg             Injection

CONTRAINDICATION

Unrestrained hypertension
Pure red cell aplasia occurred after treatment
Allergic problems

PREGNANCY

Pregnancy category is C
Usage of Darbelife   25mcg:Animal studies have results in an adverse reaction and there are no adequate studies regarding usage in pregnant women

LACTATION

When using Darbelife   40mcg             during breastfeeding has no adequate studies in women for determine infant risk.
Considered potential risk before taking the drug while breastfeeding

STORAGE AND HANDLING

Store at 2°C – 8°C (36°F to 46°F)
Do not freeze
Store the drug from light and protect from moisture

MISSED DOSE

If dose is failed to take, then have it soon before next dose arrives or swap the dose and follow normal timing.
Must Consult with the physician.

 

Feature
Brand name
Darbelife
Active substance
Darbepoetin alfa 40mcg
Manufacturer
Hetero Drugs Ltd.
Packaging
1 PFS
Product form
Injection
Strength
40mcg
Darbelife 40mcg отзывы
Add a comment
0

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educati
MEDICAL DISCLAIMERAll the contents present on the website are solely for informational purposes. Thereby, the information on the website isn’t meant to be a substitute for professional medical advice, treatment, and/or diagnosis. Please seek professiona